| Description |
CAY10583 is a potent and selective full Leukotriene B4 receptor type 2 (BLT2) agonist. CAY10583 directly promotes keratinocyte migration in vitro and accelerates wound closure in vivo. CAY10583 is a promising pharmaceutical agent for diabetic wounds[1].
|
| Related Catalog |
|
| Target |
LTB4
|
| In Vitro |
CAY10583 (1 nM-1μM; 24 hours) promotes wound closure via keratinocyte migration. And CAY10583 has no significant effect of on keratinocyte proliferation[1].
|
| In Vivo |
CAY10583 (administered topically to full-thickness wounds; 10 μM; 14 days) significantly results in a greater wound closure than the control group. The difference in wound closure between the CAY-treated group and the control group is pronounced over time until day 10. And the difference is approximately 6% at day 4 and reaches almost 20% at day 8. Notably, 100% closure was observed in the CAY-treated group at day 14[1]. Animal Model: Lewis rats (6-9 weeks of age, 180-220 g)[1] Dosage: 10 μM; 14 days Administration: Administered topically to full-thickness wounds; 10 μM; 14 days Result: Accelerated in vivo wound healing by topical application.
|
| References |
[1]. Lin Luo, et al. A synthetic leukotriene B 4 receptor type 2 agonist accelerates the cutaneous wound healing process in diabetic rats by indirect stimulation of fibroblasts and direct stimulation of keratinocytes. J Diabetes Complications. 2017 Jan;31(1):13-20
|
